메뉴 건너뛰기




Volumn 20, Issue 1, 2015, Pages 1-14

Emerging drugs for the treatment of axial and peripheral spondyloarthritis

Author keywords

Axial spondyloarthritis; Interleukin 23; Peripheral spondyloarthritis; Spondyloarthritis; TH17 pathway; TNF antagonists

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BARICITINIB; BIOSIMILAR AGENT; BRODALUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; PHOSPHODIESTERASE IV; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROFLUMILAST; SARILUMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

EID: 84923302849     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.993378     Document Type: Review
Times cited : (34)

References (113)
  • 1
    • 67449124637 scopus 로고    scopus 로고
    • The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal
    • Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68 (6): 770-6
    • (2009) Ann Rheum Dis , vol.68 , Issue.6 , pp. 770-776
    • Rudwaleit, M.1    Landewé, R.2    Van Der Heijde, D.3
  • 2
    • 67449128733 scopus 로고    scopus 로고
    • The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection
    • Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68 (6): 777-83
    • (2009) Ann Rheum Dis , vol.68 , Issue.6 , pp. 777-783
    • Rudwaleit, M.1    Van Der Heijde, D.2    Landewe, R.3
  • 3
    • 0021272107 scopus 로고
    • Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
    • van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (4): 361-8
    • (1984) Arthritis Rheum , vol.27 , Issue.4 , pp. 361-368
    • Van Der Linden, S.1    Valkenburg, H.A.2    Cats, A.3
  • 4
    • 78650679234 scopus 로고    scopus 로고
    • The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
    • RudwaleitM, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70 (1): 25-31
    • (2011) Ann Rheum Dis , vol.70 , Issue.1 , pp. 25-31
    • Rudwaleit, M.1    Van Der Heijde, D.2    Landewé, R.3
  • 5
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
    • Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54 (8): 2665-73
    • (2006) Arthritis Rheum , vol.54 , Issue.8 , pp. 2665-2673
    • Taylor, W.1    Gladman, D.2    Helliwell, P.3
  • 6
    • 79955826864 scopus 로고    scopus 로고
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    • Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70 (6): 896-904
    • (2011) Ann Rheum Dis , vol.70 , Issue.6 , pp. 896-904
    • Braun, J.1    Van Den Berg, R.2    Baraliakos, X.3
  • 7
    • 79955844276 scopus 로고    scopus 로고
    • 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
    • van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70 (6): 905-8
    • (2011) Ann Rheum Dis , vol.70 , Issue.6 , pp. 905-908
    • Van Der Heijde, D.1    Sieper, J.2    Maksymowych, W.P.3
  • 8
    • 82955236087 scopus 로고    scopus 로고
    • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
    • European League Against Rheumatism
    • Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71 (1): 4-12
    • (2012) Ann Rheum Dis , vol.71 , Issue.1 , pp. 4-12
    • Gossec, L.1    Smolen, J.S.2    Gaujoux-Viala, C.3
  • 9
    • 84889634412 scopus 로고    scopus 로고
    • Treating spondyloarthritis including ankylosing spondylitis and psoriatic arthritis to target: Recommendations of an international task force
    • Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73 (1): 6-16
    • (2014) Ann Rheum Dis , vol.73 , Issue.1 , pp. 6-16
    • Smolen, J.S.1    Braun, J.2    Dougados, M.3
  • 10
    • 0037029430 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial
    • Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-93
    • (2002) Lancet , vol.359 , Issue.9313 , pp. 1187-1193
    • Braun, J.1    Brandt, J.2    Listing, J.3
  • 11
    • 79958051264 scopus 로고    scopus 로고
    • Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized double-blind trial
    • Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63 (6): 1543-51
    • (2011) Arthritis Rheum , vol.63 , Issue.6 , pp. 1543-1551
    • Braun, J.1    Van Der Horst-Bruinsma, I.E.2    Huang, F.3
  • 12
    • 84859509505 scopus 로고    scopus 로고
    • Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
    • Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012; 71 (5): 661-7
    • (2012) Ann Rheum Dis , vol.71 , Issue.5 , pp. 661-667
    • Braun, J.1    Deodhar, A.2    Inman, R.D.3
  • 13
    • 84877606429 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: Results of a randomised placebocontrolled trial (ABILITY-1)
    • Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1). Ann Rheum Dis 2013; 72 (6): 815-22
    • (2013) Ann Rheum Dis , vol.72 , Issue.6 , pp. 815-822
    • Sieper, J.1    Van Der Heijde, D.2    Dougados, M.3
  • 14
    • 84889654076 scopus 로고    scopus 로고
    • Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
    • Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73 (1): 39-47
    • (2014) Ann Rheum Dis , vol.73 , Issue.1 , pp. 39-47
    • Landewe, R.1    Braun, J.2    Deodhar, A.3
  • 15
    • 84904957534 scopus 로고    scopus 로고
    • The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis
    • Dougados M, van der Heijde D, Sieper J, et al. The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2014; 66 (8): 2091-102
    • (2014) Arthritis Rheumatol , vol.66 , Issue.8 , pp. 2091-2102
    • Dougados, M.1    Van Der Heijde, D.2    Sieper, J.3
  • 16
    • 84860896324 scopus 로고    scopus 로고
    • Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised placebocontrolled GO-RAISE study
    • Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebocontrolled GO-RAISE study. Ann Rheum Dis 2012; 71 (6): 878-84
    • (2012) Ann Rheum Dis , vol.71 , Issue.6 , pp. 878-884
    • Braun, J.1    Baraliakos, X.2    Hermann, K.G.3
  • 17
    • 84859466376 scopus 로고    scopus 로고
    • Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement
    • Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012; 39 (4): 836-40
    • (2012) J Rheumatol , vol.39 , Issue.4 , pp. 836-840
    • Braun, J.1    Pavelka, K.2    Ramos-Remus, C.3
  • 18
    • 84898441760 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis
    • Braun J, Baraliakos X, Heldmann F, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drugs 2014; 23 (5): 647-59
    • (2014) Expert Opin Investig Drugs , vol.23 , Issue.5 , pp. 647-659
    • Braun, J.1    Baraliakos, X.2    Heldmann, F.3    Kiltz, U.4
  • 19
    • 84883746909 scopus 로고    scopus 로고
    • A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study
    • Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 10): 1605-12
    • (2013) Ann Rheum Dis , vol.10 , pp. 1605-1612
    • Park, W.1    Hrycaj, P.2    Jeka, S.3
  • 20
    • 65249142737 scopus 로고    scopus 로고
    • Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis
    • Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum 2009; 60 (4): 946-54
    • (2009) Arthritis Rheum , vol.60 , Issue.4 , pp. 946-954
    • Barkham, N.1    Keen, H.I.2    Coates, L.C.3
  • 21
    • 65249142737 scopus 로고    scopus 로고
    • Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis
    • Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum 2009; 60 (4): 946-54
    • (2009) Arthritis Rheum , vol.60 , Issue.4 , pp. 946-954
    • Barkham, N.1    Keen, H.I.2    Coates, L.C.3
  • 22
    • 84885797466 scopus 로고    scopus 로고
    • Remission and possible discontinuation of biological therapy in axial spondyloarthritis
    • Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S33-6
    • (2013) Clin Exp Rheumatol , vol.31 , Issue.4 , pp. S33-S36
    • Braun, J.1    Sieper, J.2
  • 23
    • 80051920383 scopus 로고    scopus 로고
    • Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome
    • Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011; 50 (9): 1690-9
    • (2011) Rheumatology (Oxford) , vol.50 , Issue.9 , pp. 1690-1699
    • Baraliakos, X.1    Listing, J.2    Fritz, C.3
  • 24
    • 84879071427 scopus 로고    scopus 로고
    • Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    • Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013; 15 (3): R67
    • (2013) Arthritis Res Ther , vol.15 , Issue.3 , pp. R67
    • Baraliakos, X.1    Haibel, H.2    Fritz, C.3
  • 25
    • 84899971267 scopus 로고    scopus 로고
    • The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial
    • Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014; 73 (6): 1107-13
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 1107-1113
    • Braun, J.1    Baraliakos, X.2    Hermann, K.G.3
  • 26
    • 84895490291 scopus 로고    scopus 로고
    • Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis
    • Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2013; 73 (4): 710-15
    • (2013) Ann Rheum Dis , vol.73 , Issue.4 , pp. 710-715
    • Baraliakos, X.1    Haibel, H.2    Listing, J.3
  • 27
    • 85027908446 scopus 로고    scopus 로고
    • Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
    • [Epub ahead of print]
    • Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2014. [Epub ahead of print]
    • (2014) Ann Rheum Dis
    • Haroon, M.1    Gallagher, P.2    Fitzgerald, O.3
  • 28
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
    • Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356 (9227): 385-90
    • (2000) Lancet , vol.356 , Issue.9227 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3
  • 29
    • 19044382942 scopus 로고    scopus 로고
    • IMPACT 2 Trial Investigators Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial
    • Antoni C, Krueger GG, de Vlam K, et al. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64 (8): 1150-7
    • (2005) Ann Rheum Dis , vol.64 , Issue.8 , pp. 1150-1157
    • Antoni, C.1    Krueger, G.G.2    De Vlam, K.3
  • 30
    • 26844432745 scopus 로고    scopus 로고
    • Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebocontrolled trial
    • Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum 2005; 52 (10): 3279-89
    • (2005) Arthritis Rheum , vol.52 , Issue.10 , pp. 3279-3289
    • Mease, P.J.1    Gladman, D.D.2    Ritchlin, C.T.3
  • 31
    • 84889668023 scopus 로고    scopus 로고
    • Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
    • Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73 (1): 48-55
    • (2014) Ann Rheum Dis , vol.73 , Issue.1 , pp. 48-55
    • Mease, P.J.1    Fleischmann, R.2    Deodhar, A.A.3
  • 32
    • 84905083653 scopus 로고    scopus 로고
    • Clinical efficacy radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a longterm extension of a randomised placebocontrolled trial the GO-REVEAL study
    • Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of a randomised, placebocontrolled trial, the GO-REVEAL study. Ann Rheum Dis 2014; 73 (9): 1689-94
    • (2014) Ann Rheum Dis , vol.73 , Issue.9 , pp. 1689-1694
    • Kavanaugh, A.1    McInnes, I.B.2    Mease, P.3
  • 33
    • 84885181527 scopus 로고    scopus 로고
    • Clinical efficacy radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised placebo-controlled GO-REVEAL study
    • Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013; 72 (11): 1777-85
    • (2013) Ann Rheum Dis , vol.72 , Issue.11 , pp. 1777-1785
    • Kavanaugh, A.1    McInnes, I.B.2    Mease, P.J.3
  • 34
    • 84889657887 scopus 로고    scopus 로고
    • Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: Results of the RAPID-PsA 24-week phase III doubleblind randomised placebo-controlled study of certolizumab pegol
    • van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III doubleblind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73 (1): 233-7
    • (2014) Ann Rheum Dis , vol.73 , Issue.1 , pp. 233-237
    • Van Der Heijde, D.1    Fleischmann, R.2    Wollenhaupt, J.3
  • 35
    • 84859495141 scopus 로고    scopus 로고
    • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
    • Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 (Suppl 2): i2-i45
    • (2012) Ann Rheum Dis , vol.71 , pp. i2-i45
    • Furst, D.E.1    Keystone, E.C.2    Braun, J.3
  • 36
    • 85027914552 scopus 로고    scopus 로고
    • Golimumab 3-year safety update: An analysis of pooled data from the longterm extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
    • [Epub ahead of print]
    • Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the longterm extensions of randomised, doubleblind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013. [Epub ahead of print]
    • (2013) Ann Rheum Dis
    • Kay, J.1    Fleischmann, R.2    Keystone, E.3
  • 37
    • 84920867646 scopus 로고    scopus 로고
    • Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A multicentre, open-label, randomised controlled trial
    • Coates L, Moverley A, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. Lancet 2014; 383: S36
    • (2014) Lancet , vol.383 , pp. S36
    • Coates, L.1    Moverley, A.2    McParland, L.3
  • 38
    • 84903848853 scopus 로고    scopus 로고
    • Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
    • Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; 73 (8): 1455-61
    • (2014) Ann Rheum Dis , vol.73 , Issue.8 , pp. 1455-1461
    • Ramiro, S.1    Van Der Heijde, D.2    Van Tubergen, A.3
  • 39
    • 84859255344 scopus 로고    scopus 로고
    • Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: Are there alternatives?
    • Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol 2012; 24 (3): 252-60
    • (2012) Curr Opin Rheumatol , vol.24 , Issue.3 , pp. 252-260
    • Kiltz, U.1    Heldmann, F.2    Baraliakos, X.3    Braun, J.4
  • 40
    • 84923280531 scopus 로고    scopus 로고
    • Stellungnahme der Deutschen Gesellschaft für Rheumatologie zur Einführung und Gebrauch von Biosimilars in der Therapie entzündlich-rheumatischer Erkrankungen
    • Lorenz HM, Braun J, Krüger K, Schneider M. Stellungnahme der Deutschen Gesellschaft für Rheumatologie zur Einführung und Gebrauch von Biosimilars in der Therapie entzündlich-rheumatischer Erkrankungen. Z Rheumatol 2014; 73 (9): 784-6
    • (2014) Z Rheumatol , vol.73 , Issue.9 , pp. 784-786
    • Lorenz, H.M.1    Braun, J.2    Krüger, K.3    Schneider, M.4
  • 42
    • 84923304115 scopus 로고    scopus 로고
    • Progress in biosimilar monoclonal antibody development: The infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
    • In press
    • Braun J. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 2014; In press
    • (2014) Immunotherapy
    • Braun, J.1
  • 43
    • 84923302900 scopus 로고    scopus 로고
    • New targets in psoriatic arthritis
    • In press
    • Braun J. New targets in psoriatic arthritis. Rheumatology 2014; In press
    • (2014) Rheumatology
    • Braun, J.1
  • 44
    • 85027912491 scopus 로고    scopus 로고
    • Development of a health index in patients with ankylosing spondylitis (ASAS HI): Final result of a global initiative based on the ICF guided by ASAS
    • [Epub ahead of print]
    • Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2014. [Epub ahead of print]
    • (2014) Ann Rheum Dis
    • Kiltz, U.1    Van Der Heijde, D.2    Boonen, A.3
  • 45
    • 84899825889 scopus 로고    scopus 로고
    • A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) question-naire, a 13-country EULAR initiative
    • EULAR PsAID Taskforce
    • Gossec L, de Wit M, Kiltz U, et al. EULAR PsAID Taskforce. A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) question-naire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73 (6): 1012-19
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 1012-1019
    • Gossec, L.1    De Wit, M.2    Kiltz, U.3
  • 46
    • 84887432536 scopus 로고    scopus 로고
    • Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: Changes after 2 years of tumor necrosis factor inhibitor therapy
    • Baraliakos X, Listing J, Haibel H, et al. Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol 2013; 40 (11): 1891-6
    • (2013) J Rheumatol , vol.40 , Issue.11 , pp. 1891-1896
    • Baraliakos, X.1    Listing, J.2    Haibel, H.3
  • 47
    • 84881071746 scopus 로고    scopus 로고
    • Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography
    • Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2013; 73 (10): 1819-25
    • (2013) Ann Rheum Dis , vol.73 , Issue.10 , pp. 1819-1825
    • Baraliakos, X.1    Heldmann, F.2    Callhoff, J.3
  • 48
    • 84923300192 scopus 로고    scopus 로고
    • Randomized controlled trial of adalimumab in patients with peripheral spondyloarthritis
    • Mease P, Sieper J, van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with peripheral spondyloarthritis. Arthritis Rheum 2012; 64 (suppl10): 570 doi: 10.1002/art.38305
    • (2012) Arthritis Rheum , vol.64 , pp. 570
    • Mease, P.1    Sieper, J.2    Van Den Bosch, F.3
  • 49
    • 84884411389 scopus 로고    scopus 로고
    • Genetics of ankylosing spondylitis
    • Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol 2014; 57 (1): 2-11
    • (2014) Mol Immunol , vol.57 , Issue.1 , pp. 2-11
    • Robinson, P.C.1    Brown, M.A.2
  • 50
    • 84882449068 scopus 로고    scopus 로고
    • Genetic insights into common pathways and complex relationships among immune-mediated diseases
    • Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14 (9): 661-73
    • (2013) Nat Rev Genet , vol.14 , Issue.9 , pp. 661-673
    • Parkes, M.1    Cortes, A.2    Van Heel, D.A.3    Brown, M.A.4
  • 51
    • 84896313565 scopus 로고    scopus 로고
    • The IL-23/IL-17 axis in psoriatic arthritis
    • Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014; 13 (4-5): 496-502
    • (2014) Autoimmun Rev , vol.13 , Issue.4-5 , pp. 496-502
    • Suzuki, E.1    Mellins, E.D.2    Gershwin, M.E.3
  • 52
    • 69349093225 scopus 로고    scopus 로고
    • Interleukin-17 and type 17 helper T cells
    • Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98
    • (2009) N Engl J Med , vol.361 , pp. 888-898
    • Miossec, P.1    Korn, T.2    Kuchroo, V.K.3
  • 53
    • 84863697312 scopus 로고    scopus 로고
    • IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8-entheseal resident T cells
    • Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012; 18: 1069-76
    • (2012) Nat Med , vol.18 , pp. 1069-1076
    • Sherlock, J.P.1    Joyce-Shaikh, B.2    Turner, S.P.3
  • 55
    • 66449133523 scopus 로고    scopus 로고
    • Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis
    • Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 1647-56
    • (2009) Arthritis Rheum , vol.60 , pp. 1647-1656
    • Shen, H.1    Goodall, J.C.2    Hill Gaston, J.S.3
  • 56
    • 79951835541 scopus 로고    scopus 로고
    • Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis
    • Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011; 186: 2672-80
    • (2011) J Immunol , vol.186 , pp. 2672-2680
    • Bowness, P.1    Ridley, A.2    Shaw, J.3
  • 57
    • 82455210509 scopus 로고    scopus 로고
    • Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response
    • Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 2011; 63: 3807-17
    • (2011) Arthritis Rheum , vol.63 , pp. 3807-3817
    • Zeng, L.1    Lindstrom, M.J.2    Smith, J.A.3
  • 58
    • 84858644639 scopus 로고    scopus 로고
    • Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive g/d T cells in patients with active ankylosing spondylitis
    • Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive g/d T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012; 64: 1420-9
    • (2012) Arthritis Rheum , vol.64 , pp. 1420-1429
    • Kenna, T.J.1    Davidson, S.I.2    Duan, R.3
  • 59
    • 79959207913 scopus 로고    scopus 로고
    • Analysis of IL-17 (+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
    • Appel H, Maier R, Wu P, et al. Analysis of IL-17 (+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13: R95
    • (2011) Arthritis Res Ther , vol.13 , pp. R95
    • Appel, H.1    Maier, R.2    Wu, P.3
  • 60
    • 84878527072 scopus 로고    scopus 로고
    • In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis
    • Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013; 65 (6): 1522-9
    • (2013) Arthritis Rheum , vol.65 , Issue.6 , pp. 1522-1529
    • Appel, H.1    Maier, R.2    Bleil, J.3
  • 61
    • 84855291352 scopus 로고    scopus 로고
    • Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
    • Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64: 99-109
    • (2012) Arthritis Rheum , vol.64 , pp. 99-109
    • Noordenbos, T.1    Yeremenko, N.2    Gofita, I.3
  • 62
    • 33846889522 scopus 로고    scopus 로고
    • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    • Krueger GG, Langley RG, Leonardi C, et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580-92
    • (2007) N Engl J Med , vol.356 , Issue.6 , pp. 580-592
    • Krueger, G.G.1    Langley, R.G.2    Leonardi, C.3
  • 63
    • 43449111187 scopus 로고    scopus 로고
    • PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665-74
    • (2008) Lancet , vol.371 , Issue.9625 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3
  • 64
    • 43449139402 scopus 로고    scopus 로고
    • PHOENIX 2 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2)
    • Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675-84
    • (2008) Lancet , vol.371 , Issue.9625 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3
  • 65
    • 74249094930 scopus 로고    scopus 로고
    • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    • Griffiths CE, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362 (2): 118-28
    • (2010) N Engl J Med , vol.362 , Issue.2 , pp. 118-128
    • Griffiths, C.E.1    Strober, B.E.2    Van De Kerkhof, P.3
  • 66
    • 60249084148 scopus 로고    scopus 로고
    • Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial
    • Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 (9664): 633-40
    • (2009) Lancet , vol.373 , Issue.9664 , pp. 633-640
    • Gottlieb, A.1    Menter, A.2    Mendelsohn, A.3
  • 67
    • 84883134297 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    • McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382 (9894): 780-9
    • (2013) Lancet , vol.382 , Issue.9894 , pp. 780-789
    • McInnes, I.B.1    Kavanaugh, A.2    Gottlieb, A.B.3
  • 68
    • 84899991797 scopus 로고    scopus 로고
    • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
    • Ritchlin C, Rahman P, Kavanaugh A, et al. on behalf of the PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73 (6): 990-9
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 990-999
    • Ritchlin, C.1    Rahman, P.2    Kavanaugh, A.3
  • 69
    • 84899922972 scopus 로고    scopus 로고
    • Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
    • Kavanaugh A, Ritchlin C, Rahman P, et al. on behalf of the PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73 (6): 1000-6
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 1000-1006
    • Kavanaugh, A.1    Ritchlin, C.2    Rahman, P.3
  • 70
    • 84897980960 scopus 로고    scopus 로고
    • Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
    • Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014; 73 (5): 817-23
    • (2014) Ann Rheum Dis , vol.73 , Issue.5 , pp. 817-823
    • Poddubnyy, D.1    Hermann, K.G.2    Callhoff, J.3
  • 71
    • 84871701834 scopus 로고    scopus 로고
    • Ustekinumab induction and maintenance therapy in refractory Crohn's disease
    • Sandborn WJ, Gasink C, Gao LL, et al. CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367 (16): 1519-28
    • (2012) N Engl J Med , vol.367 , Issue.16 , pp. 1519-1528
    • Sandborn, W.J.1    Gasink, C.2    Gao, L.L.3
  • 72
    • 53049091561 scopus 로고    scopus 로고
    • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    • Sandborn WJ, Feagan BG, Fedorak RN, et al. Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135 (4): 1130-41
    • (2008) Gastroenterology , vol.135 , Issue.4 , pp. 1130-1141
    • Sandborn, W.J.1    Feagan, B.G.2    Fedorak, R.N.3
  • 73
    • 84897146802 scopus 로고    scopus 로고
    • Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
    • Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133 (4): 1032-40
    • (2014) J Allergy Clin Immunol , vol.133 , Issue.4 , pp. 1032-1040
    • Sofen, H.1    Smith, S.2    Matheson, R.T.3
  • 74
    • 84899748064 scopus 로고    scopus 로고
    • Emerging evidence for critical involvement of the IL17 pathway in both psoriasis and psoriatic arthritis
    • Fitzgerald O, Winchester R. Emerging evidence for critical involvement of the IL17 pathway in both psoriasis and psoriatic arthritis. Arthritis Rheumatol 2014; 66 (5): 1077-80
    • (2014) Arthritis Rheumatol , vol.66 , Issue.5 , pp. 1077-1080
    • Fitzgerald, O.1    Winchester, R.2
  • 75
    • 84876292569 scopus 로고    scopus 로고
    • Effect of IL-17A blockade with secukinumab in autoimmune diseases
    • Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72: Suppl 2 ii116-23
    • (2013) Ann Rheum Dis , vol.72 , pp. ii116-ii123
    • Patel, D.D.1    Lee, D.M.2    Kolbinger, F.3    Antoni, C.4
  • 76
    • 84868680312 scopus 로고    scopus 로고
    • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial
    • Hueber W, Sands BE, Lewitzky S, et al. Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61 (12): 1693-700
    • (2012) Gut , vol.61 , Issue.12 , pp. 1693-1700
    • Hueber, W.1    Sands, B.E.2    Lewitzky, S.3
  • 77
    • 84875697084 scopus 로고    scopus 로고
    • Secukinumab in the treatment of noninfectious uveitis: Results of three randomized controlled clinical trials
    • Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120 (4): 777-87
    • (2013) Ophthalmology , vol.120 , Issue.4 , pp. 777-787
    • Dick, A.D.1    Tugal-Tutkun, I.2    Foster, S.3
  • 78
    • 84873168729 scopus 로고    scopus 로고
    • Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimenfinding study
    • Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimenfinding study. Br J Dermatol 2013; 168: 402-11
    • (2013) Br J Dermatol , vol.168 , pp. 402-411
    • Rich, P.1    Sigurgeirsson, B.2    Thaci, D.3
  • 79
    • 84873124241 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, doubleblind, placebo-controlled phase II doseranging study
    • Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, doubleblind, placebo-controlled phase II doseranging study. Br J Dermatol 2013; 168 (2): 412-21
    • (2013) Br J Dermatol , vol.168 , Issue.2 , pp. 412-421
    • Papp, K.A.1    Langley, R.G.2    Sigurgeirsson, B.3
  • 80
    • 84904545875 scopus 로고    scopus 로고
    • Secukinumab in plaque psoriasis-results of two phase 3 trials
    • Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371 (4): 326-38
    • (2014) N Engl J Med , vol.371 , Issue.4 , pp. 326-338
    • Langley, R.G.1    Elewski, B.E.2    Lebwohl, M.3
  • 81
    • 84891740105 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab a fully human anti-inter-leukin-17A monoclonal antibody in patients with moderate-to-severe psoriatic arthritis: A 24-week randomised doubleblind placebo-controlled phase II proof-of-concept trial
    • McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-inter-leukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, doubleblind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73 (2): 349-56
    • (2014) Ann Rheum Dis , vol.73 , Issue.2 , pp. 349-356
    • McInnes, I.B.1    Sieper, J.2    Braun, J.3
  • 82
    • 84887992906 scopus 로고    scopus 로고
    • Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised double-blind placebo-controlled trial
    • Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382 (9906): 1705-13
    • (2013) Lancet , vol.382 , Issue.9906 , pp. 1705-1713
    • Baeten, D.1    Baraliakos, X.2    Braun, J.3
  • 83
    • 84859017988 scopus 로고    scopus 로고
    • Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
    • Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366 (13): 1181-9
    • (2012) N Engl J Med , vol.366 , Issue.13 , pp. 1181-1189
    • Papp, K.A.1    Leonardi, C.2    Menter, A.3
  • 84
    • 84902209516 scopus 로고    scopus 로고
    • Brodalumab, an anti-IL17RA mono-clonal antibody, in psoriatic arthritis
    • Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA mono-clonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370 (24): 2295-306
    • (2014) N Engl J Med , vol.370 , Issue.24 , pp. 2295-2306
    • Mease, P.J.1    Genovese, M.C.2    Greenwald, M.W.3
  • 85
    • 84859073115 scopus 로고    scopus 로고
    • Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
    • Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366 (13): 1190-9
    • (2012) N Engl J Med , vol.366 , Issue.13 , pp. 1190-1199
    • Leonardi, C.1    Matheson, R.2    Zachariae, C.3
  • 86
    • 84901029678 scopus 로고    scopus 로고
    • Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: Ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab
    • Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014; 18: 1-14
    • (2014) J Cutan Med Surg , vol.18 , pp. 1-14
    • Tausend, W.1    Downing, C.2    Tyring, S.3
  • 87
    • 84860920161 scopus 로고    scopus 로고
    • Association between the IL-1 family gene cluster and spondyloarthritis
    • Monnet D, Kadi A, Izac B, et al. Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis 2012; 71 (6): 885-90
    • (2012) Ann Rheum Dis , vol.71 , Issue.6 , pp. 885-890
    • Monnet, D.1    Kadi, A.2    Izac, B.3
  • 88
    • 4344699365 scopus 로고    scopus 로고
    • Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study
    • Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63 (9): 1041-5
    • (2004) Ann Rheum Dis , vol.63 , Issue.9 , pp. 1041-1045
    • Tan, A.L.1    Marzo-Ortega, H.2    O'Connor, P.3
  • 89
    • 38649126902 scopus 로고    scopus 로고
    • Sustained response to anakinra in ankylosing spondylitis
    • Bennett AN, Tan AL, Coates LC, et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47 (2): 223-4
    • (2008) Rheumatology (Oxford) , vol.47 , Issue.2 , pp. 223-224
    • Bennett, A.N.1    Tan, A.L.2    Coates, L.C.3
  • 90
    • 13244279795 scopus 로고    scopus 로고
    • Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
    • Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64 (2): 296-8
    • (2005) Ann Rheum Dis , vol.64 , Issue.2 , pp. 296-298
    • Haibel, H.1    Rudwaleit, M.2    Listing, J.3    Sieper, J.4
  • 91
    • 79952113703 scopus 로고    scopus 로고
    • An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)
    • Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010; 29 (10): 1169-73
    • (2010) Clin Rheumatol , vol.29 , Issue.10 , pp. 1169-1173
    • Jung, N.1    Hellmann, M.2    Hoheisel, R.3
  • 92
    • 77951757221 scopus 로고    scopus 로고
    • Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial
    • Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62 (5): 1290-7
    • (2010) Arthritis Rheum , vol.62 , Issue.5 , pp. 1290-1297
    • Song, I.H.1    Heldmann, F.2    Rudwaleit, M.3
  • 93
    • 84872086509 scopus 로고    scopus 로고
    • One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare
    • Song IH, Heldmann F, Rudwaleit M, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013; 72 (2): 305-6
    • (2013) Ann Rheum Dis , vol.72 , Issue.2 , pp. 305-306
    • Song, I.H.1    Heldmann, F.2    Rudwaleit, M.3
  • 94
    • 84870318190 scopus 로고    scopus 로고
    • French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: Data from the AIR registry of the French Society of Rheumatology
    • Wendling D, Dougados M, Berenbaum F, et al. French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012; 39 (12): 2327-31
    • (2012) J Rheumatol , vol.39 , Issue.12 , pp. 2327-2331
    • Wendling, D.1    Dougados, M.2    Berenbaum, F.3
  • 95
    • 84867401161 scopus 로고    scopus 로고
    • Rituximab in psoriatic arthritis: An exploratory evaluation
    • Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012; 71 (11): 1868-71
    • (2012) Ann Rheum Dis , vol.71 , Issue.11 , pp. 1868-1871
    • Jimenez-Boj, E.1    Stamm, T.A.2    Sadlonova, M.3
  • 96
    • 79955868460 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study
    • Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108-10
    • (2011) Ann Rheum Dis , vol.70 , pp. 1108-1110
    • Song, I.H.1    Heldmann, F.2    Rudwaleit, M.3
  • 97
    • 79953701653 scopus 로고    scopus 로고
    • Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month multicenter randomized double-blind placebo-controlled phase II trial
    • Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63 (4): 939-48
    • (2011) Arthritis Rheum , vol.63 , Issue.4 , pp. 939-948
    • Mease, P.1    Genovese, M.C.2    Gladstein, G.3
  • 98
    • 0028903218 scopus 로고
    • Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
    • Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38 (4): 499-505
    • (1995) Arthritis Rheum , vol.38 , Issue.4 , pp. 499-505
    • Braun, J.1    Bollow, M.2    Neure, L.3
  • 99
    • 78049418460 scopus 로고    scopus 로고
    • Mixed response to tocilizumab for ankylosing spondylitis
    • Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010; 69 (12): 2217-18
    • (2010) Ann Rheum Dis , vol.69 , Issue.12 , pp. 2217-2218
    • Henes, J.C.1    Horger, M.2    Guenaydin, I.3
  • 100
    • 84889684742 scopus 로고    scopus 로고
    • Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials
    • Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95-100
    • (2014) Ann Rheum Dis , vol.73 , pp. 95-100
    • Sieper, J.1    Porter-Brown, B.2    Thompson, L.3
  • 101
    • 85027912860 scopus 로고    scopus 로고
    • Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebocontrolled study (ALIGN)
    • [Epub ahead of print]
    • Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebocontrolled study (ALIGN). Ann Rheum Dis 2014. [Epub ahead of print]
    • (2014) Ann Rheum Dis
    • Sieper, J.1    Braun, J.2    Kay, J.3
  • 102
    • 84882992107 scopus 로고    scopus 로고
    • Successful use of tocilizumab in a patient with psoriatic arthritis
    • Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 2013; 52 (9): 1728-9
    • (2013) Rheumatology (Oxford) , vol.52 , Issue.9 , pp. 1728-1729
    • Hughes, M.1    Chinoy, H.2
  • 103
    • 84882372494 scopus 로고    scopus 로고
    • Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: A phase II open-label study
    • Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013; 12 (8): 888-97
    • (2013) J Drugs Dermatol , vol.12 , Issue.8 , pp. 888-897
    • Gottlieb, A.B.1    Matheson, R.T.2    Menter, A.3
  • 104
    • 84865373941 scopus 로고    scopus 로고
    • Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial
    • Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380 (9843): 738-46
    • (2012) Lancet , vol.380 , Issue.9843 , pp. 738-746
    • Papp, K.1    Cather, J.C.2    Rosoph, L.3
  • 105
    • 84869014252 scopus 로고    scopus 로고
    • Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter randomized double-blind placebo-controlled study
    • Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64 (10): 3156-67
    • (2012) Arthritis Rheum , vol.64 , Issue.10 , pp. 3156-3167
    • Schett, G.1    Wollenhaupt, J.2    Papp, K.3
  • 106
    • 84899981396 scopus 로고    scopus 로고
    • Treatment of psoriatic arthritis in a phase 3 randomised placebo-controlled trial with apremilast an oral phosphodiesterase 4 inhibitor
    • Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73 (6): 1020-6
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 1020-1026
    • Kavanaugh, A.1    Mease, P.J.2    Gomez-Reino, J.J.3
  • 107
    • 84881475901 scopus 로고    scopus 로고
    • Efficacy and safety of apremilast an oral phosphodiesterase 4 inhibitor in ankylosing spondylitis
    • Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2013; 72 (9): 1475-80
    • (2013) Ann Rheum Dis , vol.72 , Issue.9 , pp. 1475-1480
    • Pathan, E.1    Abraham, S.2    Van Rossen, E.3
  • 108
    • 84865592373 scopus 로고    scopus 로고
    • Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study
    • Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167 (3): 668-77
    • (2012) Br J Dermatol , vol.167 , Issue.3 , pp. 668-677
    • Papp, K.A.1    Menter, A.2    Strober, B.3
  • 109
    • 84879988459 scopus 로고    scopus 로고
    • A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
    • Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169 (1): 137-45
    • (2013) Br J Dermatol , vol.169 , Issue.1 , pp. 137-145
    • Ports, W.C.1    Khan, S.2    Lan, S.3
  • 110
    • 84896372778 scopus 로고    scopus 로고
    • Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions
    • Menter A, Papp KA, Tan H, et al. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014; 13 (3): 252-6
    • (2014) J Drugs Dermatol , vol.13 , Issue.3 , pp. 252-256
    • Menter, A.1    Papp, K.A.2    Tan, H.3
  • 111
    • 84885798581 scopus 로고    scopus 로고
    • Withdrawal of biologic therapy in axial spondyloarthritis: The experience in established disease
    • Baraliakos X, Kiltz U, Heldmann F, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S43-6
    • (2013) Clin Exp Rheumatol , vol.31 , Issue.4 , pp. S43-S46
    • Baraliakos, X.1    Kiltz, U.2    Heldmann, F.3
  • 112
    • 84885821934 scopus 로고    scopus 로고
    • Withdrawal of biologic therapy in axial spondyloarthritis: The experience in early disease
    • Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S37-42
    • (2013) Clin Exp Rheumatol , vol.31 , Issue.4 , pp. S37-42
    • Song, I.H.1    Haibel, H.2    Poddubnyy, D.3
  • 113
    • 84877809247 scopus 로고    scopus 로고
    • Immunogenicity and autoimmunity during anti-TNF therapy
    • Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013; 12 (7): 703-8
    • (2013) Autoimmun Rev , vol.12 , Issue.7 , pp. 703-708
    • Atzeni, F.1    Talotta, R.2    Salaffi, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.